U.S. Insurance Stock News

Microsoft contract puts IREN’s AI pivot in focus IREN (NasdaqGS:IREN) is drawing fresh attention after securing a multi year US$9.7b contract with Microsoft for dedicated liquid cooled GPU clusters, a deal that supports recurring, higher margin AI infrastructure revenue. See our latest analysis for IREN. Despite some recent volatility, including a 7 day share price return decline of 17.72% and a year to date share price return decline of 20.16%, IREN’s 1 year total shareholder return of...

CoreWeave (CRWV) is drawing attention after recent trading, with the stock closing at $78.44 and showing mixed returns over the past week, month, and past 3 months as investors assess its cloud infrastructure business. See our latest analysis for CoreWeave. The 1 day share price return of 1.25% comes after a weaker 7 day share price return of 10.44%. The 1 year total shareholder return of 27.84% points to momentum that has built over a longer stretch despite recent volatility. If CoreWeave's...

Nebius Group (NasdaqGS:NBIS) is in focus after announcing a US$10b AI data center project in Lappeenranta, Finland, alongside large supply deals with Meta and Microsoft and a US$2b investment from Nvidia. See our latest analysis for Nebius Group. After a sharp rally recently, Nebius now trades at US$101.95, with a 30 day share price return of 12.02% and a year to date share price return of 13.34%. Its 1 year total shareholder return of 316.97% suggests very strong longer term momentum, while...

Incyte (NasdaqGS:INCY) released 54-week pivotal Phase 3 data from its STOP-HS program for povorcitinib in moderate to severe hidradenitis suppurativa (HS). The data show durable efficacy across multiple clinical response thresholds and improvements in patient quality of life at 54 weeks. Safety results were consistent over the long term, supporting the overall benefit risk profile of povorcitinib in HS. This is the first publication of long-term pivotal data for povorcitinib in HS ahead of...

ZIM Integrated Shipping Services recently saw sentiment soften as investors reacted to projections for a substantial year-over-year decline in its upcoming quarterly earnings and revenue. The lack of recent changes in consensus earnings estimates, alongside a Hold rating on the Zacks scale, underscores lingering uncertainty over ZIM’s near-term operating outlook. Against this backdrop of expected earnings and revenue pressure, we will examine how this cautionary earnings setup could reshape...

Recent commentary on Gold.com highlights how gold’s traditional role as a haven asset held firm despite a sharp price drop during the Middle East conflict, when liquidity needs temporarily pushed prices lower. The analysis points out that investors are now rebuilding gold exposure as concerns over global debt, currency debasement, and geopolitical risks persist, supporting renewed attention on the metal. We’ll now explore how persistent geopolitical and macroeconomic risks highlighted by...

Zai Lab announced in the past that it will collaborate with Amgen on a global Phase 1b trial combining Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan with Amgen’s IMDELLTRA for patients with extensive-stage small cell lung cancer. Separately, the FDA’s identification of dozens of Tavneos-linked liver injury cases, including severe events and deaths, raises fresh questions about Amgen’s safety and regulatory risk profile. Next, we’ll explore how the FDA’s Tavneos safety concerns could...

Oncolytics Biotech (NasdaqCM:ONCY) has completed its domestication from Canada to the United States. The company has relocated its headquarters to San Diego, with the move now effective. Oncolytics Biotech is now classified as a U.S. domestic issuer under the U.S. regulatory framework. The domestication is intended to support operational efficiencies and access to U.S. capital markets. For you as an investor, this shift touches on both regulation and capital access. Oncolytics Biotech is an...

Duke Energy (NYSE:DUK) has completed the sale of its Tennessee Piedmont Natural Gas business to Spire. The company plans to use the proceeds to support its regulated capital investment plan over the next five years. The move marks a shift in Duke Energy's portfolio toward grid and generation projects while aiming to manage customer costs. Duke Energy, trading at about $130.9 per share, is using this transaction to refine where its capital is focused. The company has delivered an 11.5%...

Coca-Cola plans a long term investment of $1 billion in South Africa to expand production and distribution capacity. The company is acquiring a majority stake in Coca-Cola Beverages Africa, covering South Africa and 14 additional African markets. The investment focuses on local hiring, operational expansion and deeper integration with regional partners over multiple years. Coca-Cola (NYSE: KO) is adding a major Africa focused chapter to its global story with this $1 billion commitment. The...

In recent weeks, Simply Good Foods has faced mounting concerns as Atkins brand sales declined in consecutive quarters and rising costs pressured margins, prompting scrutiny of its growth outlook. Beyond the immediate slowdown, the key question now is whether stronger brands like Quest and OWYN can offset Atkins’ weakness and reshape the company’s long-term earnings mix. We’ll now examine how Atkins’ sales slump and margin pressure affect Simply Good Foods’ existing investment narrative built...

If you are wondering whether Alibaba Group Holding's share price offers value right now, or if the market is pricing it fairly, this breakdown will help you connect the current price with what the business may be worth. The stock last closed at US$123.73, with returns of a 4.7% decline over 7 days, a 13.2% decline over 30 days, a 20.6% decline year to date and a 3.1% decline over the past year, set against a 32.1% gain over 3 years and a 42.2% decline over 5 years. Recent headlines around...

In March 2026, Jabil Inc. reported second-quarter results showing year-on-year growth in sales and net income, and issued third-quarter guidance calling for net revenue between US$8.10 billion and US$8.90 billion, U.S. GAAP operating income of US$398 million to US$458 million, and diluted EPS of US$2.36 to US$2.76. The company also lifted its full-year fiscal 2026 outlook to US$34.00 billion in revenue, underscoring how healthcare exposure and injector-pen manufacturing for weight-loss drugs...

Abbott Laboratories (ABT) just expanded its cancer diagnostics reach through a new integration with Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers streamlined access to its Precision Oncology testing portfolio. See our latest analysis for Abbott Laboratories. Despite the oncology integration and other recent moves such as the ESOP related shelf registration and investment in Whoop, Abbott’s 30 day share price return of 10.29% and year to date share price return of...

Planet Labs PBC (PL) is back in focus after filing a US$680.7m shelf registration tied to an ESOP related offering, alongside fresh quarterly results, wider net losses, and new revenue guidance. See our latest analysis for Planet Labs PBC. After the shelf filing and earnings release, Planet Labs PBC’s 1-day share price return of 9.87% contrasts with a 7-day share price return of negative 13.18%. A 90-day share price return of 55.73% sits alongside a 1-year total shareholder return of about...

KULR Technology Group (KULR) closed FY 2025 with fourth quarter revenue of US$2.9 million and a basic EPS loss of US$0.97, alongside a trailing twelve month EPS loss of US$1.56 on revenue of US$16.2 million. Over the last few quarters, the company has reported revenue between US$2.4 million and US$6.9 million per quarter, while quarterly EPS has ranged from a loss of US$0.54 to a gain of US$0.22. This leaves investors focusing on how quickly these top line changes might translate into...

FitLife Brands (FTLF) has just closed out FY 2025 with fourth quarter revenue of US$25.9 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$81.5 million and EPS of US$0.68 that investors will be watching against the prior year’s figures. Over recent quarters the company has seen revenue move from US$15.0 million in Q4 FY 2024 to US$25.9 million in Q4 FY 2025, while quarterly EPS shifted from US$0.23 to US$0.17, setting the backdrop for the latest full year read on...

Check Point Software Technologies (CHKP) closed out FY 2025 with fourth quarter revenue of US$744.9 million and basic EPS of US$2.85, while full year trailing EPS reached US$9.85 on revenue of US$2.7 billion and earnings grew 25% over the past 12 months. Over the last few reported periods, revenue has moved from US$703.7 million in Q4 2024 to US$744.9 million in Q4 2025, with quarterly basic EPS ranging from US$1.77 in Q1 2025 to US$3.34 in Q3 2025 and trailing net income rising from US$845.7...

Dawson Geophysical (DWSN) closed out FY 2025 with fourth quarter revenue of US$26.9 million and basic EPS of US$0.02, alongside net income of US$0.6 million. This set a cleaner finish to a year where the trailing twelve month figures still show a loss of US$1.9 million on US$75.6 million of revenue and a basic EPS loss of US$0.06. Over recent quarters the company has seen quarterly revenue range from US$9.9 million to US$26.9 million, with EPS moving between a loss of US$0.08 and a profit of...

IDEAYA Biosciences (IDYA) recently reported the first patient enrolled in a Phase 1 trial combining IDE849, a DLL3 targeting antibody drug conjugate, with PARG inhibitor IDE161 in several DLL3 upregulated solid tumors. See our latest analysis for IDEAYA Biosciences. The Phase 1 combination update has come as IDEAYA’s share price has eased slightly in the short term, with a 7 day share price return of 3.47% and a 1 year total shareholder return close to 100%. This reflects how recent trial...

ABM Industries stock: recent returns and business mix in focus ABM Industries (ABM) has drawn investor attention after a one-month return of about a 13% decline, adding to a past three-month drop of roughly 9%. This performance has invited closer inspection of its fundamentals. See our latest analysis for ABM Industries. With the share price at $38.70, ABM Industries has seen weaker momentum recently, with a 30 day share price return of a 13.44% decline and a 1 year total shareholder return...

If you are wondering whether Kosmos Energy's share price still reflects its underlying worth, the recent moves in the stock make that question especially timely. The stock last closed at US$2.78, with returns of 2.2% over 7 days, 19.3% over 30 days, 211.4% year to date and 23.6% over 1 year, set against a 64.3% decline over 3 years and a 9.2% decline over 5 years. Recent news coverage has focused on Kosmos Energy's positioning within the energy sector and how investors are reacting to...

In late March 2026, Rockwell Automation released a new season of its ROKStudios executive video series, spotlighting manufacturing leaders across EMEA discussing cyber resilience, workforce transformation, packaging innovation, and the shift from traditional automation to more autonomous industrial operations. This content push underscores how Rockwell is positioning itself at the center of industry debates on digital complexity, resilience, and AI-enabled industrial workflows, aligning its...

In late March 2026, UWM Holdings CEO Mat Ishbia and SFS Holding Corp sold 3,001,722 Class A shares, shortly after the company reported fourth-quarter 2025 revenue of US$945.00 million that exceeded forecasts and announced advisory and proxy work around its proposed acquisition of Two Harbors Investment Corp. This combination of insider selling, stronger-than-expected quarterly results, and an active acquisition process highlights a period of meaningful corporate change and heightened...